Lazard Asset Management LLC Sells 922 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Lazard Asset Management LLC trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 66.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 476 shares of the company’s stock after selling 922 shares during the quarter. Lazard Asset Management LLC’s holdings in Krystal Biotech were worth $74,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in KRYS. Covestor Ltd raised its holdings in Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after buying an additional 642 shares during the period. KBC Group NV grew its stake in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after buying an additional 297 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after buying an additional 433 shares during the period. US Bancorp DE lifted its stake in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after acquiring an additional 82 shares during the last quarter. Finally, Certuity LLC bought a new stake in shares of Krystal Biotech during the fourth quarter worth $214,000. Institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on KRYS shares. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 6th. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, Citigroup cut their price target on Krystal Biotech from $215.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, May 16th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average price target of $211.13.

Krystal Biotech Trading Down 0.2%

Shares of NASDAQ KRYS opened at $125.05 on Monday. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $219.34. The stock’s fifty day simple moving average is $161.34 and its two-hundred day simple moving average is $166.79. The stock has a market capitalization of $3.61 billion, a PE ratio of 41.82 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. On average, equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68% decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).